RLFTF News and Press, MindMaze Therapeutics Holding SA

GENEVA, SWITZERLAND / ACCESS Newswire / December 23, 2025 / MindMaze Therapeutics Holding SA (SIX: MMTX ) (MindMaze Therapeutics or the Company), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases, today outlined the evolution of its g...

GENEVA, SWITZERLAND / ACCESS Newswire / December 15, 2025 / MindMaze Therapeutics Holding SA (SIX: MMTX ) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, preci...

Shareholders approve all EGM proposals related to the combination with NeuroX Business combination expected to close in December 2025 Relief to be renamed MindMaze Therapeutics Holding SA upon closing New board and executive committee members announced Companies to hos...

RLF-OD032 demonstrated bioequivalence to KUVAN ® Powder Study results support planned 505(b)(2) NDA submission in early 2026 GENEVA, SWITZERLAND / ACCESS Newswire / October 29, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the...

GENEVAD, SE / ACCESS Newswire / August 14, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today announce...

GENEVA, SWITZERLAND / ACCESS Newswire / August 11, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief, or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today ...

2025-07-29 03:24:59 ET More on Relief Therapeutics Holding SA Financial information for Relief Therapeutics Holding SA Read the full article on Seeking Alpha For further details see: Relief Therapeutics reports proposed business combination with NeuroX

NeuroX recently acquired the assets and operations of MindMaze, a world-renowned leader in evidence-based neurotherapeutic solutions for neurological diseases and brain disorders Business combination to create an expanded, SIX-listed, commercial-stage, AI-driven, scalable health tech compa...

GENEVA, SWITZERLAND / ACCESS Newswire / June 20, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief or the Company), a biopharmaceutical company committed to delivering innovative treatment options for select specialty, unmet and rare diseases, today ann...

Shareholders approved all proposals by a large majority GENEVA, SWITZERLAND / ACCESS Newswire / June 12, 2025 / RELIEF THERAPEUTICS Holding SA (SIX: RLF )(OTCQB: RLFTF )(OTCQB: RLFTY ) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative ...